Recent investigations have centered on the convergence of GLP-1|glucose-dependent insulinotropic polypeptide|glucagon receptor agonist therapies and dopaminergic neurotransmission. While GIP stimulators are widely employed for treating type 2 diabetes, their unexpected effects on reward circuits, specifically mediated by dopaminergic systems, are a